Press Releases

Press Releases

DateTitle 
Aug 04, 2020
BURLINGAME, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference . The presentation will be on Tuesday, August 11 from
Jul 30, 2020
Provides Update on CPI-006 Phase 1 COVID-19 Study Conference Call   Today at 4:30 p.m. ET / 1:30 p.m. PT   BURLINGAME, Calif. , July 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced
Jul 23, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , July 23, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30,
Jul 07, 2020
Approach stimulates immune response by activating B cells to enhance antibody production Safety and scientific basis supported by ongoing cancer clinical trial Study designed to evaluate anti-viral antibody response in up to 30 COVID-19 patients with mild to moderate symptoms Company to host
May 29, 2020
Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders Data Includes Additional Patients with Advanced Refractory Renal Cell Cancer, Supporting Earlier Results
May 27, 2020
BURLINGAME, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient
May 13, 2020
BURLINGAME, Calif. , May 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient
Apr 30, 2020
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the
Apr 22, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Mar 05, 2020
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the
Feb 28, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals , Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology
Feb 19, 2020
BURLINGAME, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Richard A. Miller , M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted
Feb 13, 2020
BURLINGAME, Calif. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated
Feb 01, 2020
BURLINGAME, Calif. , Feb. 01, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated